NIH - BPH TRIAL

POST END-OF-STUDY VISIT INVENTORY

This form should be completed at any visit that takes place after the end-of-study visit. Separation visits will be scheduled for all patients who are accessible whether or not they have continued on coded medications after the end-of-study visit.

Part I / IDENTIFICATION	
A. Patient Identification	
1. Patient number (PATID)	clinic patient
2. Patient's initials (INITS)	first last
3. Patient's date of birth (DOB)	month day year
B. <u>Visit Information</u>	month day year
1. Date of visit (EVSTDT)	month day year
2. Week of visit (EVIWK)	
3. Type of visit (Check all that apply.)	Follow-up Visit (EVITYP)Separation Visit (EVITYPS)
If this is a Follow-up Visit with or without Separation Visit, If this is a Separation Visit ONLY, SKIP to section E.	CONTINUE.
Part II / VITAL SIGNS	
C. <u>Blood Pressure Readings</u>	
1. Supine Blood Pressure (After lying 5 minutes)	
a. Blood Pressure Reading (EBPLS)/(EBPLD)	mmHg
b. Heart Rate (EBPLHR)	bpm
2. Standing Blood Pressure (Immediately)	
a. Blood Pressure Reading 1 (EBPSS1)/(EBPSD1)	mmHg
b. Heart Rate 1 (EBPSHR1)	bpm
Wait 2 minutes	
c. Blood Pressure Reading 2 (EBPSS2)/(EBPSD2)	mmHg
d. Heart Rate 2 (EBPSHR2)	bpm

Patient number Date of visit month day year	BPH FORM F07.1 July, 2001 Page 2 of 3
D. Orthostatic Hypotension	
1. Did the patient have orthostatic hypotension? (EORTHYP) YES NO 2 2	
Orthostatic hypotension is defined as a decrease of more than 20mmHg in supine to standing systolic blood pressure or a decrease of more than 10mmHg in supine to standing diastolic by pressure (in either standing blood pressure reading) or the development of significant posture hypotension.	olood
Part III / MEDICATION DISPENSING AND COMPLIANCE AND ADVERSE EVENTS	
E. General Medication Dispensing Information YES NO	
1. Were coded medications dispensed post End-of-Study? (EGMCODM)	
If YES, CONTINUE. If NO, SKIP to section J.	
2. Is the patient currently taking coded doxazosin? (EGMCODD)	
3. Is the patient currently taking coded finasteride? (EGMCODF)	
4. Number of days since last visit (EGMDAYS)	
F. <u>Doxazosin Compliance</u>	
If doxazosin was dispensed at the last visit, returned and/or dispensed today, CONTINUE. If not, SKIP to Section G.	
1. Dose of doxazosin (ECDDOSE) 1 mg 2 mg 4 mg 8 mg 1 2 3 4 mg 8 mg	
2. Number of doxazosin tablets dispensed at the last visit (ECDDISL)	
Number of doxazosin tablets returned today (ECDRET)	
4. Compliance (ECDCOMP) tabs dispensed (#2) - tabs returned (#3) days since last visit (question E) X 100	ó
5. Number of doxazosin tablets dispensed today (ECDDIST)	
G. Finasteride Compliance	
If finasteride was dispensed at the last visit, returned and/or dispensed today, CONTINUE. If not, SKIP to Section H.	
Number of finasteride tablets dispensed at the last visit (ECFDISL)	
Number of finasteride tablets returned today (ECFRET)	
3. Compliance (ECFCOMP) tabs dispensed (#1) - tabs returned (#2) days since last visit (question E) X 100	,
4. Number of finasteride tablets dispensed today (ECFDIST)	

Patient number			ſ	Date of visit	month	day	year		BPH FORM July, 20 Page 3	001
Concomitant M Is the patient coded medical If YES, list be	currently ta ations? (EC		dication	other than the	е		YES	NO 2		
a. (ECMCC	ONA) (I	ECMCODA)	f.	(ECMCC	NF)	(ECMCO	DF)			
b. (ECMCC	ONB) (F	ECMCODB)	Į g	. (ECMCC	NG)	(ECMCO	DG)			
c. (ECMCC	ONC) (F	ECMCODC)	h	· (ECMCC	ONH)	(ECMCO	DH)			
d. (ECMCC	OND) (I	ECMCODD)	i.	(ECMCC	ONI)	(ECMCO	DI)			
e. (ECMC	ONE) (ECMCODE)	j	(ECMCC	ONJ)	(ECMCC	DJ)			
Has the patient Adverse Events	<u>3</u>	`	ŕ		·	·	1	2		
1. Since the last scheduled follow-up visit, has the patient had any adverse experiences, drug reactions, side effects, abnormal laboratory values, hospitalizations, other complications or pre-existing conditions that worsened? (EAELVST)										
lf YES, an Adverse	Event Rep	ort (Form E0	5) MUST	be complete	ed.					
If this is a separation visit, CONTINUE. J. Treatment Group Disclosure									1	
For all patients the study computer.	treatment o	group assignr	ment sho	ould be obtain	ned from	the MTO	PS staf	f webs	ite or	
Was the patie If YES, CON		of his treatm	nent grou	up assignmer	nt? (ETG		YES	NO 2		ı
a. Treatment		gnment discl	osed to	patient (ETG	DAPT)	[[[Do	nasterid	acebo n & placeb e & placeb n & finaste	00
Initials of person completing form (FORMIN) first last Form entered in computer?										
Signature of P.I.						Data				